2024-02-222024-02-222020-01Dbaibo, G. vd. (2020). "Quadrivalent influenza vaccineprevents illness and reduces healthcare utilizatverse geographic regions during five influenza seasons a randomized clinical trial". The Pediatric Infectious Disease Journal, 39(1), e1-e10.0891-36681532-0987https://journals.lww.com/pidj/Fulltext/2020/01000/Quadrivalent_Influenza_Vaccine_Prevents_Illness.17.aspxhttps://hdl.handle.net/11452/39898Çalışmada 38 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.Background: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6-35 months of age in a phase III, observer-blind trial. Methods: The aim of this analysis was to estimate vaccine efficacy (VE) in preventing laboratory-confirmed influenza in each of 5 independent seasonal cohorts (2011-2014), as well as vaccine impact on healthcare utilization in 3 study regions (Europe/Mediterranean, Asia-Pacific and Central America). Healthy children were randomized 1:1 to IIV4 or control vaccines. VE was estimated against influenza confirmed by reverse transcription polymerase chain reaction on nasal swabs. Cultured isolates were characterized as antigenically matched/mismatched to vaccine strains. Results: The total vaccinated cohort included 12,018 children (N = 1777, 2526, 1564, 1501 and 4650 in cohorts 1-5, respectively). For reverse transcription polymerase chain reaction confirmed influenza of any severity (all strains combined), VE in cohorts 1-5 was 57.8%, 52.9%, 73.4%, 30.3% and 41.4%, respectively, with the lower limit of the 95% confidence interval >0 for all estimates. The proportion of vaccine match for all strains combined in each cohort was 0.9%, 79.3%, 72.5%, 24.1% and 28.6%, respectively. Antibiotic use associated with influenza illness was reduced with IIV4 by 71% in Europe, 36% in Asia Pacific and 59% in Central America. Conclusions: IIV4 prevented influenza in children 6-35 months of age in each of 5 separate influenza seasons in diverse geographical regions. A possible interaction between VE, degree of vaccine match and socioeconomic status was observed. The IIV4 attenuated the severity of breakthrough influenza illness and reduced healthcare utilization, particularly antibiotic use.eninfo:eu-repo/semantics/closedAccessDisease attenuationVaccine efficacyInfluenzaSeasonal variationHealthcare utilizationModerate-to-severeAntibiotic-resistanceConfirmed influenzaYoung-childrenInfectionEfficacyInfantsDiseaseVisitsBurdenImmunologyInfectious diseasesPediatricsFemaleGeography, medicalHumansInfluenza A virusInfluenza B virusInfluenza vaccinesInfluenza, humanMaleOutcome assessment, health carePatient acceptance of health carePublic health surveillanceSeasonsVaccines, inactivatedArticle0005038032000012-s2.0-85076327447e-1e-1039131725115https://doi.org/10.1097/INF.0000000000002504ImmunologyInfectious diseasesPediatricsHuman Influenza; Macacine Herpesvirus 1; Hemagglutination Inhibition TestsInactivated vaccineInfluenza vaccineControlled studyInfluenza B virusFemaleGeneticsHealth surveyHumanImmunologyInfluenzaInfluenza A virusMaleMedical geographyPatient attitudeRandomized controlled trialSeason